<DOC>
	<DOCNO>NCT00038454</DOCNO>
	<brief_summary>To evaluate efficacy Hemolink™ combination Intraoperative Autologous Donation ( IAD ) versus control ( IAD alone ) facilitate avoidance allogeneic RBC transfusion follow primary CABG surgery</brief_summary>
	<brief_title>Phase II Study To Evaluate The Safety Efficacy Hemoglobin Raffimer Patients Undergoing First Time CABG Surgery</brief_title>
	<detailed_description>All subject consent take part protocol meet inclusion/exclusion criterion undergo IAD harvest follow post-induction IAD harvest calculation . IAD blood collect citrate-phosphate-dextrose-adenine 1 ( CPDA-1 ) blood bag . All subject receive volume Hespan® equal volume IAD harvest ( maximum 1 liter ) perform result harvest calculation ( 0–1200 mL inclusive ) . Additional volume replacement require owe IAD &gt; 1000mL perform crystalloid , require . Subjects randomize one two treatment arm ( Hemolink™ arm control arm ) upon meet transfusion trigger first time CPB . Randomization administer centrally . Subjects transfuse upon reach predetermine transfusion trigger , reflect decrease hemoglobin concentration and/or oxygenation :</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>Subjects meet follow criterion eligible inclusion study : Written Informed Consent . Age 18 80 year , inclusive . Scheduled primary CABG surgery CPB candidate IAD . Postinduction hemoglobin , allow collection 01200 mL inclusive IAD blood achieve target hemoglobin 7.5 g/dL 15 minute onCPB . For woman childbearing potential , able use use highlyeffective contraceptive method time study screen week 4 8 post CABG surgery ( followup visit ) . Note : International Conference Harmonization ( ICH ) guideline define highlyeffective contraceptive method one failure rate le one percent use consistently correctly Subjects meeting follow criterion exclude study : Previous treatment Hemolink ( tm ) hemoglobinbased oxygen carrier . Participation clinical trial investigational drug , device , medical procedure within two month prior enrollment , concurrent participation study . History stroke residual paralysis transient ischemic attack within 6 month prior surgery . Congenital coagulation disorder treatment Coumadin within seven day prior surgery . Alcohol drug use within 12 month prior enrollment , investigator considers abusive . Planned simultaneous surgery ( e.g. , valve repair carotid endarterectomy ) . Emergency CABG . Previous surgery use sternotomy . Current pregnancy nursing . Chronic pancreatitis without pancreatic insufficiency . Any subject medically cleared surgical procedure intraoperative autologous donation eligible enrollment study . Medical clearance require follow : No current congestive heart failure , New York Heart Association class IV . Most recent ( within 1 year surgery ) ejection fraction must less equal 25 percent , leave ventricular function grade 4 . No current uncontrolled hypertension . No current severe pulmonary disease render subject high risk require prolonged postoperative ventilation . No serum creatinine &gt; 2.0 mg/dL ( 177 umol/L ) . No know AST ALT bilirubin &gt; 3 time upper limit normal . No uncontrolled angina within 24 hour prior surgery despite maximal medical treatment , and/or presence intraaortic balloon pump preoperatively . No history transmural myocardial infarction within five day prior schedule CABG surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>Oxygen Therapeutics</keyword>
	<keyword>CABG</keyword>
	<keyword>Transfusion</keyword>
</DOC>